Briumvi (ublituximab-xiiy) may be more effective than Kesimpta (ofatumumab) or Ocrevus (ocrelizumab) at preventing disability progression among people with relapsing forms of multiple sclerosis (MS), according to an indirect comparison of clinical trial data. “In the absence of head-to-head clinical trials, [matching-adjusted indirect comparison] provides a valuable statistical…
Discussion
Anti-CD20 therapies, a type of treatment approved for multiple sclerosis (MS), may be highly effective in MS partly because they reduce the immune system’s ongoing response to the Epstein-Barr virus (EBV), a well-established risk factor for MS. That’s according to a study involving nearly 200 people that found…
Discussion
Parental stress may help explain the link between disease-related difficulties and lower self-esteem in children and adolescents with pediatric-onset multiple sclerosis (POMS), a study in Israel found. The findings suggest that higher fatigue, greater disease severity, and slower processing speed in children were each associated with greater parental stress. Greater…
Discussion
I’ve been quiet lately. It’s not because I haven’t had anything to write about, but because life decided to throw multiple crises into the mix. Over the past couple of months, my mom underwent both thyroid and major spinal surgery, my cat decided to eat part of her litter mat…
Discussion
Generic medications are expected to be equivalent to their brand-name counterparts — but a new study found that generic versions of certain treatments for multiple sclerosis (MS) were linked to greater variability in disease biomarkers than the original drugs. “We identified differences in circulating protein biomarker variability between brand…
Get regular updates to your inbox.
